Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2025 07:48 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of Centene Corporation (NYSE: CNC); Flywire Corporation (NASDAQ: FLYW); Replimune Group, Inc. (NASDAQ: REPL); and Sable Offshore Corporation (NYSE: SOC): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Centene Corporation (NYSE: CNC): Grabar Law Office is investigating claims on behalf of shareholders of Centene Corporation (NYSE: CNC). The...
July 30, 2025 08:49 ET | Source: Grabar Law Office

Important Notice to Short and Long-Term Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); Flywire Corporation (NASDAQ: FLYW); Replimune Group, Inc. (NASDAQ: REPL); and Sable Offshore Corporation (NYSE: SOC): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE: DV): Grabar Law Office is investigating whether certain officers and directors of DoubleVerify...
July 30, 2025 08:36 ET | Source: Bleichmar Fonti & Auld

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Replimune Group, Inc. investors that lost money are notified to contact BFA Law before the September 22, 2025 securities fraud class action deadline.
July 28, 2025 10:00 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, July 28, 2025 (GLOBE NEWSWIRE) -- Alto Neuroscience, Inc. (NYSE: ANRO): Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience,...
July 28, 2025 08:36 ET | Source: Bleichmar Fonti & Auld

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. investors that lost money are notified to contact BFA Law before the September 22, 2025 securities fraud class action deadline.
July 27, 2025 09:58 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, July 27, 2025 (GLOBE NEWSWIRE) -- Alto Neuroscience, Inc. (NYSE: ANRO): Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO)....
July 26, 2025 07:08 ET | Source: Bleichmar Fonti & Auld

REPL CLASS ACTION ALERT: FDA Response Letter Leads to Replimune Group, Inc. Class Action – Investors are Notified to Contact BFA Law by September 22 Deadline

Replimune Group, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.
July 25, 2025 17:04 ET | Source: Portnoy Law

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Replimune Group, Inc....
July 24, 2025 08:07 ET | Source: Bleichmar Fonti & Auld

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Replimune Group, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.
July 22, 2025 11:03 ET | Source: Block & Leviton LLP

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Block & Leviton is investigating Replimune Group, Inc. (Nasdaq: REPL) for potential securities law violations. Investors should contact the firm.